Sponsored Join Now

Feline Diabetes Mellitus and What’s New with Dr. Andrew Bugbee | VETgirl Veterinary Continuing Education Podcasts

In this VETgirl podcast, we talk to Dr. Andrew Bugbee, DACVIM about diabetes mellitus in your feline patients, and what you need to know. Find out what some of the challenges are when it comes to discussing diabetes with cat owners, and what matters most to cat owners when they get the diagnosis of diabetes mellitus? After all, what’s so hard about managing diabetes in cats? Learn about Bexacat, and how it may change the way we treat this disease, compared to how we treat with insulin. What’s the “right” patient for Bexacat, and how do we monitor cats on SGLT2 inhibitors like Bexacat? Learn what’s new in feline diabetes mellitus with this VETgirl podcast!

Today’s VETgirl podcast is sponsored by Elanco. A global animal health leader, we rigorously innovate to improve the health of animals, benefit our customers, support our causes and strengthen our communities. We are excited about bringing new solutions to pet owners, veterinarians and the animals we all love. Our latest innovation in the diabetes mellitus arena promises to change the way we think about treating this disease in cats forever.

Please note: Dr. Bugbee has been compensated for his participation in this podcast.

Elanco Bexacat

Indication: Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
Important Safety Information:
Before using this product, it is important to read the entire product insert, including the boxed warning. See package insert for full prescribing information.
Cats treated with Bexacat may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of Bexacat. Do not use Bexacat in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of Bexacat in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of Bexacat, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death. Sudden onset of hyporexia/anorexia, lethargy, dehydration, diarrhea that is unresponsive to conventional therapy, or weight loss in cats receiving Bexacat should prompt immediate discontinuation of Bexacat and assessment for diabetic ketoacidosis, regardless of blood glucose level. Bexacat should not be initiated in cats with pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis. Due to risk of severe adverse reactions, do not use Bexacat in cats with evidence of hepatic disease or reduced renal function. Consult a physician in case of accidental ingestion by humans.
Bexacat is a trademark of Elanco or its affiliates. PM-US-23-0825

Only VETgirl members can leave comments. Sign In or Join VETgirl now!